Keloidal scars are abnormal scars of uncertain etiology with a predilection for certain racial groups. Although many articles have been published on the management of these scars, there are no definitive treatment protocols. Our objective was to examine the scientific quality of the literature on therapy for keloidal scars. There are many problems with the study designs of existing keloidal scar research. These include lack of consistent disease definitions and outcome measures, inadequate follow-up, and inconsistent therapeutic interventions. Suggestions are given for future studies. (J Am Acad Dermatol 2002;46:S63-97.)Le texte complet de cet article est disponible en PDF.
| This article is part of a supplement supported by Galderma Laboratories.
| Disclosures: Dr Shaffer has no conflicts of interest to disclose. Drs Taylor and Cook-Bolden are clinical investigators for Allergan, Galderma, and Hill. Dr Taylor is a member of the Advisory Board for Galderma, Medicis, Proctor and Gamble, and Roche, and is a speaker for Allergan, Galderma, Medicis, Novartis, and Roche. Dr Cook-Bolden is a member of the Advisory Board for Galderma and Connetics, and is a speaker for Galderma, Dermik, and Roche.
| Joseph J. Shaffer, MD, Department of Dermatology, St Luke's-Roosevelt Hospital Center, 1090 Amsterdam Ave, Suite 11D, New York, NY 10025.
| Supported by a grant from Galderma Laboratories, LP.